Quince Therapeutics, Inc. (NASDAQ:QNCX) Stock Now Rated “Moderate Buy” by Sell-Side Analysts

Shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) have been assigned an average recommendation of “Moderate Buy” from the fourteen analysts that are presently covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, three have assigned a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $189.88.

A number of research analysts have recently commented on the company. Rodman & Renshaw assumed coverage on Quince Therapeutics in a report on Thursday, September 24th. They set a “buy” rating and a $70.00 price objective on the stock. Oppenheimer initiated coverage on Quince Therapeutics in a research report on Wednesday, July 29th. They set an “outperform” rating and a $82.00 target price on the stock. Zacks Research raised shares of Quince Therapeutics to a “hold” rating in a report on Thursday, October 1st. Raymond James Financial started coverage on Quince Therapeutics in a research report on Friday, October 9th. They set an “outperform” rating and a $72.00 target price for the company. Finally, Wall Street Zen lowered shares of Quince Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 22nd.

Quince Therapeutics Price Performance

QNCX opened at $31.73 on Friday. The stock has a fifty day moving average of $30.69 and a 200-day moving average of $45.07. The firm has a market capitalization of $32.27 million, a P/E ratio of -0.20 and a beta of 1.33. Quince Therapeutics has a 12-month low of $15.10 and a 12-month high of $909.98.

Quince Therapeutics (NASDAQ:QNCX) last posted its quarterly earnings results on Friday, August 14th. The company reported ($12.31) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($28.02) by $15.71. On average, analysts expect that Quince Therapeutics will post -8.39 earnings per share for the current fiscal year.

Institutional Trading of Quince Therapeutics

An institutional investor recently bought a new position in Quince Therapeutics stock. BlackRock Inc. bought a new position in shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 1,702 shares of the company’s stock, valued at approximately $31,000. BlackRock Inc. owned approximately 0.17% of Quince Therapeutics at the end of the most recent quarter. 30.75% of the stock is currently owned by institutional investors.

About Quince Therapeutics

Quince Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for rare diseases with significant unmet medical needs. The company is advancing therapies designed to address underlying disease mechanisms and improve outcomes for patients with serious genetic and neurological disorders.

Quince’s lead program is based on the EryDex drug-delivery platform, which uses a patient’s own red blood cells to encapsulate and gradually release a corticosteroid in the body.